Changes of Tryptase in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization

Xu-Li Min,Lin Yang,Xiao-Ming Zhang,Yi Zhou,Nan-Dong Miao,Yong-Jun Ren,Hao Xu,Kang Liu,Juan Peng,Ke Yang
DOI: https://doi.org/10.21037/tcr.2017.08.43
2017-01-01
Translational Cancer Research
Abstract:Background: To explore the dynamic changes of tryptase in hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) treatment and to determine whether the tryptase level changes in response to TACE. Methods: The serum levels of tryptase were detected in 40 patients with HCC 1 day prior to TACE procedure, as well as 1, 7, and 28 days after TACE treatment by using enzyme-linked immune-sorbent assays (ELISAs). The difference in serum tryptase levels before and after chemoembolization therapy was examined using analysis of variance. A t-test was performed for comparisons between two response groups. Results: The levels of tryptase in this group 1 day before TACE, and 1, 7 and 28 days after TACE were 4.85 +/- 2.46, 3.32 +/- 1.76, 3.15 +/- 1.67 and 4.85 +/- 2.50 ng/mL, respectively. The tryptase levels before and after TACE treatment were significantly different (F = 48.461, P = 0.000). The levels of tryptase decreased markedly on day 1 and 7 after TACE and were recovered to the pre-TACE level on day 28 after TACE. Partial response (PR), stable disease (SD) and progressive disease (PD) were observed in 13 (32.5%), 12 (30.0%) and 15 (37.5%) patients, respectively; none of the patients achieved a complete response (CR). The serum levels of tryptase in responsive group (CR + PR) were significantly lower than those in non-responsive group (SD + PD) 28 days after TACE (3.54 +/- 1.16 vs. 5.48 +/- 2.74 ng/mL, respectively; t = 2.426, P = 0.020). Conclusions: The level of serum tryptase in patients with HCC after TACE shows a dynamic change that may be used to evaluate the response to TACE.
What problem does this paper attempt to address?